The reduction effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose levels in healthy individuals

Food Science and Biotechnology

Volumn 23, Issue 3, 2014, Pages 971-973

  Jo, Sung Hoon ^a   Ha, Kyoung Soo ^a   Lee, Jong Wook ^b   Kim, Young Cheul ^c   Apostolidis, Emmanouil ^d   Kwon, Young In ^a  

^a Hannam University   (South Korea)

^b Kunpoong Bio Co Ltd   (South Korea)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d FRAMINGHAM STATE UNIVERSITY   (United States)

Author keywords

antihyperglycemia; chitosan oligosaccharide; GO2KA1; postprandial hyperglycemia

Indexed keywords

BLOOD; CHITOSAN; OLIGOSACCHARIDES;

ANTIHYPERGLYCEMIA; BLOOD GLUCOSE LEVEL; CHITOSAN-OLIGOSACCHARIDE; GO2KA1; HEALTHY INDIVIDUALS; LOW MOLECULAR WEIGHT CHITOSANS; PLASMA CONCENTRATION; POSTPRANDIAL HYPERGLYCEMIA;

GLUCOSE;

EID: 84903826303     PISSN: 12267708     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10068-014-0131-3     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention. National diabetes prevention. Available from: http://www. cdc. gov/diabetes/prevention/prediabetes. html. Accessed Sep. 15, 2013.
2. World Health Organization. Diabetes. Available from: http://who. int/mediacentre/factsheets/fs312/en/index. html. Accessed Apr. 20, 2013.
3. American Diabetes Association. Diagnosing diabetes and learning about prediabetes. Available from: http://www. diabetes. org/diabetesbasics/diagnosis/?loc=DropDownDB-diagnosis. Accessed Apr. 2013.
4. Maeda Y, Kimura Y. Antitumor effects of various low-molecularweight chitosans are due to increased natural killer activity of intestinal intraepithelial lymphocytes in sarcoma 180-bearing mice. J. Nutr. 134: 945-950 (2004).
5. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am. J. Physiol- Endoc. M. 284: E671-E678 (2003).
6. Ko GT, Cockram CS, Chan JC. How to minimize missing those subjects with high 2HR plasma glucose but 'normaľ fasting plasma glucose levels? J. Med. 32: 53-65 (2001).
7. Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res. Clin. Pract. 40 (Suppl. 1): S21-S25 (1998).
8. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care 26: 881-885 (2003).
9. Xia W, Liu P, Zhang J, Chen J. Biological activities of chitosan and chitooligosaccharides. Food Hydrocolloid. 25: 170-179 (2011).
10. Qin C, Du Y, Xiao L, Li Z, Gao X. Enzymic preparation of watersoluble chitosan and their antitumor activity. Int. J. Biol. Macromole. 31: 111-117 (2002).
11. Kim SK, Rajapakse N. Enzymatic production and biological activities of chitosan oligosaccharides (COS): A review. Carbohyd. Polym. 62: 357-368 (2005).
12. Kumar SG, Rahman MA, Lee SH, Hwang HS, Kim HA, Yun JW. Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. Proteomics 9: 2149-2162 (2009).
13. Kondo Y, Nakatani A, Hayashi K, Ito M. Low molecular weight chitosan prevents the progression of low dose streptozotocininduced slowly progressive diabetes mellitus in mice. Biol. Pharmaceut. Bull. 23: 1458-1464 (2000).
14. Jo SH, Ha KS, Moon KS, Kim JG, Oh CG, Kim YC, Apostolidis E, Kwon YI. Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model. Int. J. Mol. Sci. 14: 14214-14224 (2013).